Bacteria isilated from the airways of paediatric patients with bronchiectasis according to HIV status by Verwey, Charl
i 
 
BACTERIA ISOLATED FROM THE AIRWAYS OF 
PAEDIATRIC PATIENTS WITH BRONCHIECTASIS 
ACCORDING TO HIV STATUS 
 
Charl Verwey 
Student Number: 0517054E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of 
the Witwatersrand, Johannesburg, in partial fulfilment of the requirements for 
the degree of Masters of Medicine in the branch of Paediatrics 
Johannesburg 2015 
ii 
 
DECLARATION 
 
I, Charl Verwey, declare that this research report is my own work. It is being submitted for 
the degree of Masters of Medicine in the branch of Paediatrics in the University of the 
Witwatersrand, Johannesburg. It has not been submitted for any degree or examination at 
this or any other university. 
 
 
 
Signature: _________________________ 
 
________ day of ________________2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Dedicated to Sanushka Naidoo, Akhil Carter Verwey and Kiran Luke Verwey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ABSTRACT 
 
Background: It is routine to take airway samples from patients with bronchiectasis to 
determine the bacteria that colonize their airways. This guides the choice of antimicrobials to 
use when they have chest infection.   It is not known whether there is a difference between the 
number, type and density of bacteria found in the airways of human immunodeficiency virus 
(HIV) positive and negative patients with bronchiectasis. Objective: To determine the bacteria 
isolated from the airways of children with bronchiectasis according to their HIV status.  
Methods: Records of children under 16 years of age with the diagnosis of bronchiectasis who 
had been seen by division of paediatric pulmonology at CHBAH between April 2011 and 
March 2013 were reviewed. Data were collected on the patient demographics, HIV status and 
characteristics of the airway samples collected from all the patients. Data collected on the 
airway samples included number of samples collected per patient, type and quality of the 
samples collected, number and type of organisms cultured and density of individual organisms 
cultured. Comparisons between HIV negative and positive patients were made. Results: A total 
of 78 patients with bronchiectasis were seen by the division of pulmonology over this 2 year 
period. Their mean age was 9.7±3.3 years. The majority of patients (79.5%) were HIV positive. 
175 samples were collected and of these 85.7% were expectorated sputum. Gram negative 
bacteria (71.6%) were more common than gram positive bacteria (28.4%). H. influenzae was 
the most common bacteria identified (36.0%) followed by S. pneumoniae (13.1%), S. aureus 
(11.3%) and M. catarrhalis (10.8%). When comparing HIV positive and negative patients with 
bronchiectasis there was no difference in the number, type and density of bacteria isolated. 
Conclusion: Number, type and density of bacteria isolated in the airways of children with 
bronchiectasis is not associated with the HIV status of the patient. 
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CHAPTER 1 
1.0 INTRODUCTION 
1.1 Definition and Presentation of Bronchiectasis 
Bronchiectasis is a chronic suppurative pulmonary disorder that can generally be defined 
as an irreversible dilatation of the central and peripheral airways. It is characterized 
clinically by a chronic cough of more than four weeks duration with purulent sputum 
production, coarse crepitations on chest auscultation and features of chronic suppurative or 
obstructive lung disease
1-9
 such as digital clubbing, lung hyperinflation, increased antero-
posterior diameter of the chest and a Harrison’s sulcus. Patients with bronchiectasis often 
present with recurrent chest infections. There may also be non-specific features such as 
exertional dyspnoea and growth failure. Radiologically it can be defined as a reversal in 
the ratio between the diameter of the lumen of a bronchus and the diameter of the adjacent 
pulmonary artery on computed tomography scan (signet ring sign). Usually this ratio is < 1 
but in bronchiectasis it is > 1.
10
 There is also a loss of tapering of bronchi as they extend to 
the periphery of the lung and areas of hyperlucency suggestive of small airway obstruction 
with air-trapping. Pathologically it is defined as a permanent dilatation of the large and 
medium sized airways and a reduction of the generations of subdivisions of one or more 
bronchi due to destruction of the structural elements within the bronchial wal1
1, 11
 from 
repeated episodes of lower airway infection and the accompanying inflammation.
12
   
 
It is associated with periodic infectious exacerbations which are defined as an increase in 
the severity and the wet character of the cough.
13, 14
 There is chronic bacterial colonization 
of the bronchi and an increase in inflammatory cells, T lymphocytes and neutrophils, and 
mediators, interleukin-8 and tumour necrosis factor alpha, in the bronchial mucosa and 
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bronchial walls.
15, 16
  This leads to a vicious cycle of recurrent chest infections and chronic 
inflammatory changes leading to the eventual destruction of the structural elements within 
the bronchial wall. 
 
1.2 Epidemiology of Bronchiectasis 
The incidence of non-cystic fibrosis (CF) bronchiectasis in children has not been well 
described. Field in 1927 reported the incidence of bronchiectasis in children under the age 
of fifteen in England and Wales as 7 per million children.
1
 With improvement in housing 
conditions, sanitation, nutrition and the availability of antibiotics and immunisations 
against many of the organisms responsible for the development of bronchiectasis the 
incidence of bronchiectasis in developed countries has decreased.
17-20
  In Finland the 
annual incidence of bronchiectasis in children under the age of 15 years between 1983 and 
1992 was only 0.5 per 100 000.
18
 In the USA the overall prevalence was reported as 52 per 
100 000 irrespective of age.
21
 Eastham reported a prevalence of one in 5 800 in Newcastle 
on Tyne in the  north west on England.
22
 
 
A few studies have shown that bronchiectasis is more common in developing countries and 
communities
5, 23
 and in indigenous socioeconomically disadvantaged communities of 
developed countries.
19, 24
 This was illustrated by Twiss in 2005 who reported an overall 
incidence of 3.7 per 100 000 children under the age of fifteen years in New Zealand. When 
divided along socioeconomic and indigenous lines the results were 17.8 per 100 000 in 
children of Pacific Island heritage and 4.8 per 100 000 in children of Maori descent 
compared to only 1.5 per 100 000 in children of European descent who are of higher 
socioeconomic status. This was statistically significant.
19
 The children of Pacific Island 
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Heritage or from Maori descent were from families who had twice the average 
unemployment rate and were seven times more likely to live in homes where there were 
more than two occupants per bedroom. In another study from New Zealand Edwards 
showed similar results where he reported an overall prevalence of 1 in 5 900 in children 
under the age of fifteen years of age in Auckland but the prevalence was high at 1 in 1 875 
and 1 in 4 244 for children from Pacific Island and Maori descent (low socioeconomic 
status) respectively compared to 1 in 24 900 reported in those of European descent (high 
socioeconomic status).
6
 Similarly Chang reported an overall prevalence of bronchiectasis 
of 4.9 per 1000 live births in children under the age of fifteen in Central Australia, but in 
the indigenous children the incidence was 14.7 per 1000.
4
 
 
1.3 Pathogenesis of Bronchiectasis 
Chronic airway inflammation leading to bronchiectasis may be as a result of primary lung 
abnormalities that predispose the patient to recurrent or severe infections or due to normal 
lungs with either an abnormal host immune response or after an overwhelming severe 
lower respiratory tract infection in a previously normal lung.
4-9, 14, 16, 17, 19, 22, 24-28
 In a 
number of children with bronchiectasis no cause can be found.
4-9, 14, 16, 17, 19, 22, 25-27, 29
 
 
Cystic fibrosis and primary ciliary dyskinesia cause bronchiectasis due to impairment of 
mucous clearance from the airways.
8, 17, 27, 29
 Chronic aspiration syndromes in the 
neurologically impaired as well in children with anatomical abnormalities such as tracheo-
oesophageal fistula or laryngo-tracheal clefts may lead to bronchiectasis.
4, 6, 7, 9, 16, 17, 27, 29
 
Bronchiectasis may also develop in children with congenital lung abnormalities
4, 17, 19, 22
 or 
after foreign body aspiration.
5, 6, 8, 16, 24
 
4 
 
 
Abnormalities in the immune system of a patient can lead to more recurrent and severe 
infections in a patient with normal underlying lungs and this can lead to the development 
of bronchiectasis.
5-9, 16, 17, 22, 25-27, 29
 Humoral immunodeficiencies leading to a shortage or 
absence of immunoglobulins is an important cause of recurrent chest infections that 
eventually can lead to bronchiectasis if not managed adequately. These include IgG 
(including subtypes), IgM and IgA deficiencies.
4, 30
 Examples of acquired 
immunodeficiencies are HIV infection, prolonged steroid usage and malignancies. 
 
1.4 Bronchiectasis and Infections 
Bronchiectasis has classically been described to be associated with infections due to 
measles virus, adenovirus
31
 and  Bordetella pertussis.
1
 Staphylococcus aureus (S. aureus), 
Haemophilus influenzae (H. influenzae), Streptococcus pneumoniae (S. pneumoniae), 
respiratory syncytial virus and influenza virus infections have also been associated with the 
development of bronchiectasis.
6
 Mycobacterium tuberculosis (M. tuberculosis) infection 
can also be complicated by bronchiectasis  either  due to extra-luminal airway obstruction 
by tuberculous lymph nodes or by severe parenchymal tuberculous infection.
25, 32, 33
 In 
developing countries infections remain the most common cause of bronchiectasis.
6, 8, 25
 
 
In HIV positive patients the cause of bronchiectasis is usually due to recurrent and severe 
respiratory tract infections on the background of an abnormal immune system. A study 
done by Berman et al in 2007 in Florida USA looked at the risk factors for developing 
bronchiectasis in HIV positive patients.
34
 It was found that HIV positive patients with 
bronchiectasis were more likely to have had recurrent pneumonia (P = < 0.001), more 
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episodes of pneumonia (P = < 0.001) and were more likely to have more profound 
immunosuppression than HIV positive patients without bronchiectasis. In this study HIV 
positive patients with bronchiectasis were also more likely to have had a diagnosis of 
lymphocytic interstitial pneumonitis (P = 0.005). Patients with HIV have a higher 
incidence of pneumonia and develop more severe pneumonia.
35
 The incidence of TB is 
also much higher in patients with bronchiectasis.
35, 36
 South Africa has a very high 
prevalence of HIV positive patients. The National HIV and syphilis prevalence survey 
released by the National Department of Health in 2008 estimated that the national HIV 
positive prevalence in South Africa stands at 28.0% (CI: 26.9 - 29.1%).
37
  
 
In South Africa antiretroviral drugs (ARVs) were only accessible to the general population 
in 2004. This led to a large cohort of patients in whom the introduction of ARVs was 
delayed. Due to the delay in diagnosis and a lack of adequate treatment for their HIV these 
patients often develop features consistent with chronic lung disease. Jeena et al described 
the chronic lung diseases found in children mean (range) age 36 months (18–144) with 
HIV in Durban before anti-retroviral medication was available in South Africa
38
. They 
reported that 57% of the HIV infected patients investigated had lymphocytic interstitial 
pneumonitis and 19% of these patients also had bronchiectasis. 14% of the patients had 
another interstitial pneumonia and in this study 0% had bronchiectasis in isolation.  A 
study from Zimbabwe by Ferrand et al describing chronic lung disease in adolescents with 
vertically transmitted HIV showed that 100 of 116 (86%) met their definition of chronic 
lung disease.
39
 The most common high resolution chest CT abnormality found (55%) was 
that of decreased attenuation suggesting small airway disease. 43% of patients who had 
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symptoms of chronic lung disease also had high resolution chest CT changes in keeping 
with bronchiectasis.
39
 
 
1.5 Bacterial Colonization of the Airway and Bronchiectasis 
Irrespective of the cause of the bronchiectasis the structural damage to the airways results 
in bacterial colonisation of the airways and predisposes the patient to repeated lower 
respiratory tract infections that can cause further damage to the lungs.
12
 In order to limit 
the damage to the airways and lung parenchyma, episodes of acute infective exacerbations 
should be treated early and aggressively. Acute infective exacerbations are defined as an 
increase in the cough frequency and the character of the sputum produced as well as a 
change in the volume of the sputum produced and occasionally also a change in the chest 
auscultatory findings.
13, 14
 Knowing which bacteria are found in the airways of patients 
with bronchiectasis is important in defining empiric antibiotic guidelines for acute 
infective exacerbations. 
 
The airway colonizing bacteria resulting in acute infective exacerbations in patients with 
CF-related bronchiectasis have been extensively described, with colonization from an early 
age with S. aureus and H. influenza being common, and followed closely by Pseudomonas 
aeruginosa (Ps. aeruginosa).   
 
Studies in adult non-CF related bronchiectasis patients have shown that H. influenzae, Ps. 
aeruginosa and S. pneumoniae are the most common organisms isolated.
40
 Adult patients 
with CF-related bronchiectasis are more likely to be colonised with Ps. aeruginosa than 
patients with non-CF related bronchiectasis (84% vs 29.7% (P = <0.05)).
41
 They are also 
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more likely to have S. aureus colonisation than in non-CF related bronchiectasis (65% vs 
5% (P = <0.05)).
41
 
 
There have been a few studies that have described the organisms colonizing the airways in 
paediatric non-CF related bronchiectasis.
6, 19, 22, 29, 42
 Two studies from Turkey reported that 
in children presenting with non-CF related bronchiectasis the most common bacteria found 
in the airways were H. influenzae (37%), Ps. aeruginosa (29%), S. aureus (13%), S. 
pneumoniae (8%), Klebsiella (8%) and Enterobacter (4%).
8, 42
 Eastham et al reported that 
H. influenzae and S. pneumoniae were the most common organisms isolated from children 
with non-CF related bronchiectasis from Newcastle, England.
22
 Studies from other 
developed countries reported H. influenzae, S. pneumoniae, Moraxella catarrhalis (M. 
catarrhalis), S. aureus and Ps. aeruginosa as being the most prevalent organisms.
6, 14, 16, 19, 
26, 29
 
 
Bacterial carriage may change in individuals over time with the carriage of H. influenzae 
decreasing in children with bronchiectasis from both Alaska and Australia, that of S. 
pneumoniae remaining stable and that of S. aureus increasing over a 4 – 6 year period.43 
 
The bacteria in the airways of children with HIV associated chronic lung disease have 
recently been described.
39, 44
 Ferrand et al described the organisms found in the airways of 
54 adolescents with vertically transmitted HIV in Zimbabwe.
39
 A positive bacterial sputum 
culture was reported in 17 (31%) of these patients with H. influenzae, S. aureus, M. 
catarrhalis, Ps. aeruginosa, S. pneumoniae, Klebsiella pneumoniae (K. pneumoniae) and 
Listeria monocytogenes being the organisms reported. Masekela et al looked at a cohort of 
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HIV infected children in South Africa and found that the most common organisms were H. 
influenzae and H. parainfluenzae which accounted for approximately 49% of the 
organisms cultured.
44
 
 
It is not clear if there is a difference in organisms colonizing the airways between HIV 
infected and HIV uninfected patients.  
 
1.6 Management of Children with Bronchiectasis in Relation to Airway Colonization 
Patients with bronchiectasis who are asymptomatic are not placed on antibiotics when 
airway samples return a positive culture result. When there is an acute deterioration in their 
clinical condition as judged by an increase in the volume of sputum production, change in 
sputum colour, fever, increase in respiratory rate or work of breathing, radiological 
changes or deterioration in pulmonary function a course of antibiotics will be started 
guided by the microscopy, culture and sensitivity results of the previous sputum cultures of 
the individual patient.  
 
Having the information regarding the bacteria found in the airways of HIV infected and 
HIV uninfected patients with bronchiectasis will be vital in making the choice of which 
antibiotics to use in those patients with bronchiectasis who suffer an acute exacerbation. 
The majority of patients presenting with bronchiectasis to the paediatric pulmonology 
service at Chris Hani Baragwanath Academic Hospital (CHBAH) are HIV positive and 
whether to treat the HIV infected and HIV uninfected patients with bronchiectasis 
differently or with the same antibiotics is a question that needs answering.  
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CHAPTER 2 
2.0 MATERIALS AND METHODS 
2.1 Aim 
To determine the bacteria found in airway samples of paediatric patients with 
bronchiectasis seen at Chris Hani Baragwanath Academic Hospital according to their HIV 
status. 
 
2.2 Objectives 
1. To describe the bacteria found in the airway samples of paediatric patients with 
bronchiectasis at Chris Hani Baragwanath Academic Hospital. 
2. To compare the type and density of bacteria found in the airway samples of patients with 
bronchiectasis who are HIV infected to those who are HIV uninfected.  
 
2.3 Study Design 
A retrospective observational study of children with bronchiectasis who had been admitted 
to the paediatric wards or were attending the paediatric pulmonology clinic at Chris Hani 
Baragwanath Academic Hospital (CHBAH) from 01 April 2011 to 31 March 2013. 
 
2.4 Study Setting 
CHBAH is a tertiary hospital in the public sector in Soweto, Gauteng. It is a referral centre 
for patients from the surrounding primary and secondary hospitals that serve the southern 
part of Gauteng, as well as from numerous secondary hospitals in the surrounding 
provinces. The majority of patients who attend CHBAH paediatric pulmonology clinic 
with bronchiectasis are from the local Soweto community. Referrals to the paediatric 
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pulmonology clinic at CHBAH are received either from the in-house service or from the 
primary and secondary hospitals in the hospital drainage area. In-house referrals are 
received from one of four acute general paediatric wards or from other sub-specialty 
services, for example the haematology-oncology unit or the infectious diseases unit. The 
infectious diseases unit runs the hospital’s paediatric HIV clinic.  
 
2.5 Definition of Bronchiectasis 
The diagnosis of bronchiectasis was suspected on history and clinical examination and 
confirmed by radiological findings with the aid of a chest x-ray (CXR) or a computed 
tomography scan (CT) of the lungs. Clinical features that were suggestive of bronchiectasis 
included a chronic cough productive of purulent sputum, signs of chronic suppurative lung 
disease such as digital clubbing, increased chest antero-posterior diameter, a Harrison’s 
sulcus and coarse crackles on lung auscultation. CXR changes included dilated peripheral 
airways, cystic changes in the lung fields and features of air-trapping and hyperinflation 
such as air anterior to the cardiac shadow, narrowing of the mediastinal shadow and 
flattening of the diaphragm. In patients who had a chest CT done, diagnosis was made on 
features such as tram-tracking, signet ring sign and gross dilatation and cystic changes of 
the large airways. All patients involved in this study were assessed for bronchiectasis by 
the investigator, CV.   
 
2.6 Study Population 
All children under the age of 16 years with a diagnosis of bronchiectasis who were either 
admitted to CHBAH and referred to the paediatric pulmonology service or who attended 
the paediatric pulmonology clinic at this hospital  from 01 April 2011 to 31 March 2013. 
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2.6.1 Inclusion criteria 
1. Children under 16 years of age with bronchiectasis. 
2. Children admitted in CHBAH or who attend the paediatric pulmonology clinic at 
CHBAH and who have had at least one airway sample collected for microscopy and 
culture.  
3. Children whose airway samples were processed at the National Health Laboratory 
Services (NHLS) based at CHBAH. 
 
2.6.2 Exclusion criteria 
1. Children with the diagnosis of bronchiectasis who had airway samples collected but 
processed and analysed at a laboratory other than NHLS at CHBAH. 
2. Children with bronchiectasis in whom CF had been confirmed. 
 
2.7 Sampling Technique and Materials 
As part of hospital protocol, airway samples were taken from all patients who had been 
diagnosed with bronchiectasis. The first sample was taken when the patient initially 
presented to the general paediatric wards for an acute lower respiratory tract infection and 
is subsequently diagnosed with bronchiectasis or when the patient arrived as a referral to 
the paediatric pulmonology clinic for the investigation and management of their 
bronchiectasis. Samples were then taken on a regular basis, approximately every three 
months, and during every acute exacerbation or admission. This was done for airway 
bacterial surveillance. 
 
Airway samples were collected by one of the following methods:  
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- Spontaneous expectoration: the patient spontaneously coughs and the 
expectorate is captured in a sample bottle. 
- Induced sputum: the patient is given a short-acting beta-agonist (salbutamol 
200µg via metered dose inhaler) followed 10-15 minutes later by 5ml 5% 
hypertonic saline nebulisation. The patient is then asked to spontaneously 
cough and the expectorate is collected into a specimen bottle. 
- Tracheal aspirate: airway samples are collected after instilling 1-2 ml 0.9% 
saline through an endotracheal tube in an intubated patient and then suctioning 
the sample into a sputum trap. 
- Broncho-alveolar lavage during bronchoscopy: 0.9% saline is instilled into the 
airways of a patient during bronchoscopy. 10-20 ml 0.9% saline is instilled 
depending on the patient’s weight. Negative suction is applied via the 
bronchoscope and the samples are collected in a sputum trap. 
All samples were sent to the NHLS laboratory at CHBAH. 
 
Procedure for processing Samples at the NHLS laboratory: 
The most purulent portion of the sample is placed on a microscope slide with the aid of a 
disposable loop or a sterile swab. The sample is gently rolled on the slide and is allowed to 
air dry. The slide is stained with the Gram’s stain method. Gram’s crystal violet solution is 
added onto the slide and applied for one minute. It is then washed off with water. Gram’s 
iodine solution is applied to the slide and allowed to remain for one minute before being 
washed off. The slide is then flooded with Gram’s decolouriser for ten seconds or less until 
no more Gram’s crystal violet washes off. The Gram’s decolouriser is washed off with 
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water. Gram’s safranin solution is applied to the slide and removed by washing off with tap 
water after thirty seconds. After this staining procedure the slide is ready for interpretation. 
 
The samples are examined under a light microscope. The number of polymorphonuclear 
and squamous epithelium cells per low power field (10x magnification) is counted. A total 
of ten fields are counted per sample. The Bartlett’s scoring system is then used to 
determine the likelihood of the sample being of upper or lower respiratory tract origin. The 
number of neutrophils per low power field are counted and a score of 0, +1 or +2 assigned 
depending on whether there are <10, 10-25 or >25 neutrophils per low power field. The 
number of squamous epithelial cells per low power field is then counted and a score of 0, -
1 or -2 assigned depending whether there are <10, 10-25 or >25 squamous epithelial cells 
per low power field. The scores from the polymorphonuclear cells and the squamous 
epithelial cells are then added together. A score of 0 or less is indicative of a sample 
originating from the upper respiratory tract and represents a sample with a lack of active 
inflammation or one that is contaminated with saliva. A score of 1 or more is indicative of 
a lower respiratory tract sample and of a sample with features of active inflammation.  
 
The Gram’s stains are further examined to determine the bacterial and cellular density of 
the sample. The number of neutrophils per low power field are counted and a score of 1+, 
2+ or 3+ assigned depending on whether there are <10, 10-25 or >25 neutrophils per low 
power field. The bacterial density is reported by assigning a symbol +, ++ or +++ for the 
following scenarios: + for when bacteria are present but not on every field observed under 
oil immersion 100x objective, ++ for when bacteria are present in every field but not in 
large amounts or +++ for when bacteria are present in all fields in large amounts. 
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Furthermore if the organisms on the slide have stained blue-purple they are gram positive 
organisms and if the organisms stain red-pink they are gram negative organisms. 
 
With all samples the following media was inoculated by selecting the most purulent 
portion of the sample and transferring it with a disposable loop onto the media: 5% horse 
blood agar which is incubated in CO2 at 35
o
C, MacConkey agar which is incubated 
aerobically at 35
o
C and Bacitracin heated blood agar which is incubated in CO2 at 35
o
C. 
Broncho-alveolar lavage samples were centrifuged at 1 500 rpm for five minutes before 
plating on the abovementioned media. All inoculated media were read after 24 and 48 
hours. Identification of the bacterial organism was done if any of the plates yielded 
positive growth. Positive cultures were further quantified to establish the density of the 
bacterial growth in the culture. Culture density is reported as +, ++ and +++. + is when less 
than 10 colony forming units (CFUs) are counted on the initial inoculum, ++ is when 10 – 
99 CFUs are counted on the initial inoculum and +++ is when ≥100 CFUs are counted on 
the initial inoculum. Bacterial sensitivity testing was done on samples when requested or in 
the following cases: when S. pneumoniae, H. influenzae or M. catarrhalis had been 
identified, when gram negative organisms were identified in a sample with a positive 
Bartlett score, or when S. aureus was identified without the presence of concomitant 
normal oral flora. 
 
Broncho-alveolar lavage samples were additionally plated on a Sabouraud dextrose agar 
for fungal culture. These media were incubated in CO2 at 35
o
C. Fungal cultures on samples 
other than broncho-alveolar lavage samples were not done routinely but were done when 
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requested. Specific anaerobic cultures were not routinely performed due to the technical 
difficulties and low yield of this test.  
 
HIV testing was routinely done on all patients who were admitted to the paediatric wards. 
HIV testing was performed as per National Department of Health Guidelines. HIV 
serology with the ELISA method was done for children older than eighteen months of age 
with a confirmatory serology test (HIV combination Ab/ P24 Ag) performed if an ELISA 
was reactive.  HIV PCR (qualitative) testing was done for children under eighteen months.  
 
2.8 Data Collection Procedures 
Data was collected from the patient’s paediatric pulmonology file and from the 
computerized NHLS results database. The paediatric pulmonology patient files are kept in 
the paediatric pulmonology department. Each patient has a paediatric pulmonology file 
opened on first presentation to the paediatric pulmonology service whether as an inpatient 
in the wards or as a referral to the paediatric pulmonology clinic. The results from the 
computerised NHLS results database were accessed via computers in each hospital ward as 
well as in the outpatient and paediatric clinics area. 
 
The following data were collected from the patients’ paediatric pulmonology file and from 
the computerised NHLS results database: patient demographic characteristics, radiological 
features, including chest x-ray and chest computed tomography scans, data on previous and 
current tuberculosis treatment and laboratory findings including HIV status, CD4 count, 
viral load, number and type of sputum samples collected, sputum microscopy and sputum 
culture results. All samples collected from patients were included in the analysis. This 
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included multiple samples from the same patient. Comparisons were made between all 
individual samples as well as between multiple samples from an individual patient. The 
initial CD4 count and viral load on presentation to the paediatric pulmonology team was 
used for analysis. 
 
2.9 Data Analysis 
All data were entered into an Excel spreadsheet and all patient identifiers were removed. 
The individual patient identifiers were only available to the principal investigator and were 
held in a secure database. Patient details were removed from the database prior to the data 
analysis. The data capture sheet for this study can be viewed in Appendix 1.  
 
Statistical analysis was performed using Statistica Version 12. Description of the data was 
summarized using the mean and standard deviations for continuous variables with normal 
distribution; median, interquartile range and range for continuous data without normal 
distribution and proportions and percentages was used for categorical variables.   
 
Comparisons between HIV positive and negative patients with bronchiectasis were 
performed using the Student t-test for continuous variables with normal distribution and 
Mann-Whitney U test for those without normal distribution. The Chi-square or Fisher’s 
exact test was for categorical variables. The differences were considered to be statistically 
significant when the p-value was less than 0.05.  
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2.10 Ethics Considerations 
2.10.1 Permission 
In preparation for conducting of the study the investigator, attended a Good Clinical 
Practice course in 2012 (Appendix 2). Permission to perform the study was obtained from 
the Hospital Protocol Review Committee (Appendix 3) and the Human Research Ethics 
Committee of the University of the Witwatersrand (Clearance certificate number: 
M130415, Attached as Appendix 4). 
  
2.10.2 Confidentiality 
A list, which contained the names and hospital numbers of the patients, was kept 
confidential by the author. This list was used only during retrieving of the medical records.  
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CHAPTER 3  
3.0 RESULTS 
3.1 Number of Patients Enrolled and their Demographic Characteristics  
Seventy-eight patients with non-CF bronchiectasis had airway samples analysed at 
CHBAH from 01 April 2011 to 31 March 2013 and were included in the study. Thirty-
seven (47.4%) were from admission in the paediatric wards and 40 (51.4%) were being 
seen at the paediatric pulmonology clinic. Thirty-seven (47.4%) had bronchiectasis 
confirmed by means of a CT chest. The male-to-female ratio was 0.8:1.  The mean age of 
the patients was 9.7±3.3 years. Seventy-five (96.2%) were of African descent and 3 (3.8%) 
were of coloured descent (Table 3.1).  
 
3.2 HIV Status of Patients with Bronchiectasis 
All 78 patients were tested for HIV.  Sixty-two (79.5%) of them were HIV positive and 16 
(20.5%) were HIV negative (Table 3.1).  Fifty-five (88.7%) and 50 (80.6%) HIV positive 
patients had CD4 count percentage and HIV viral load recorded respectively.   The mean 
CD4 percentage in these patients was 15.8±12.1% and the median viral load was 17 974.5 
copies per millilitre (IQR 183 395). In 35 (56.5%) of the HIV positive patients the duration 
of ARV treatment was known. The mean duration of ARV treatment in these patients was 
52.1±39.1 months. 
 
There was no significant statistical differences between the HIV positive and HIV negative 
patients with regards to sex (p=0.353). There was a trend for the HIV positive patients to 
be older at presentation than the HIV negative patients, with a mean age in HIV positive 
patients of 10.0±3.2 years compared to  8.3±3.4 years in HIV negative patients  (p=0.051).  
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Table 3.1 Demographic Characteristics and HIV Results of Study Patients (n=78) 
Characteristics Total Number (%) P - value 
 All  
(N = 78) 
HIV +ve 
(N = 62)  
HIV –ve 
(N = 16)  
HIV +ve vs. 
HIV -ve 
Age in years 
(mean) 
- <1 year 
- 1-5 years 
- > 5 years 
9.7±3.3* 
 
  0 
  6 (7.7) 
72 (92.3) 
10.0±3.2* 
 
  0 
  4 (6.5) 
58 (93.5) 
8.3±3.4* 
 
  0 
  2 (12.5) 
14 (87.5) 
P = 0.051 
Sex:  
- Male 
- Female 
 
35 (44.9) 
43 (55.1) 
 
29 (46.8) 
33 (53.2) 
 
  6 (37.5) 
10 (62.5) 
 
P = 0.353 
 
Race:  
- African 
- Coloured 
 
75 (96.2) 
  3 (3.8) 
 
59 (95.2) 
  3 (4.8) 
 
16 (100) 
  0  
 
P = 0.497 
 
* Mean ± Standard deviation 
 
3.3 Underlying Conditions Associated with Bronchiectasis in this Cohort 
Sixty-two (79.5%) patients were HIV positive. Forty-seven (60.3%) patients had 
previously been treated for TB and 7 (9.0%) patients were on TB treatment when they 
presented to paediatric pulmonology. Among the 47 patients who had previously been 
treated for TB, 35 (44.9%) had received a single course of TB treatment, 7 (9.0%) had 
received two courses, 2 (2.6%) had received three courses of TB treatment and data 
regarding the number of previous TB treatment courses was missing in 3 cases. HIV 
positive patients were more likely than HIV negative patients to have had previous TB 
treatment (p=0.016), but there was no statistical difference regarding the number of 
previous TB treatments received (p=0.567) or the number of patients currently on TB 
treatment (p=0.949). 
 
Three (3.8%) patients had post-infectious bronchiectasis: 1 developed bronchiectasis post-
measles infection and 2 with respiratory papillomatosis, 3 (3.8%) patients had a primary 
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immunodeficiency: 2 with agammaglobulinaemia and 1 with a natural killer cell 
deficiency, 1 (1.3%) had an acquired immunodeficiency post-chemotherapy for a Wilms 
tumour and 1 (1.3%) had an aspiration syndrome. In one patient no cause could be found. 
There were no patients with post-foreign body bronchiectasis, cystic fibrosis, primary 
ciliary dyskinesia or congenital airway abnormalities.  
 
3.4 Sample Collection  
3.4.1 Number of Samples Collected 
A total of 175 samples were collected from the 78 patients. The median number of samples 
collected per patient was two. Thirty-four patients (43.6%) had one sample collected, 22 
(28.2%) had 2 samples collected, 8 (10.3%) had three, and 14 (18.0%) had more than three 
samples collected (Table 3.2). There was no statistical difference between the number of 
samples collected from HIV positive and HIV negative patients (p=0.701).  
 
3.4.2 Type of Specimen  
One hundred and fifty (85.7%) were expectorated or induced sputum specimens and 25 
(14.3%) were broncho-alveolar lavage (BAL) specimens (Table 3.2). There were more 
HIV –ve  patients who had specimens collected using BAL, compared to expectorated or 
induced specimens, than HIV +ve patients (p=<0.05).  
 
3.4.3 Quality of Specimens: Bartlett Score  
Of the 150 samples on which quality assessment was performed 11 (7.3%) had a Bartlett 
score of -1 or -2 indicating a sample representative of the upper airways. Twenty-nine 
(19.3%) had a Bartlett score of 0 in which it is difficult to assess the representation of 
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upper or lower airways. One hundred and nine (72.7%) had a Bartlett score of +1 or +2 
indicating a sample representative of the lower airways. Information on Bartlett score was 
missing on one patient.  There was no statistical significant difference in the Bartlett score 
between HIV positive and HIV negative patients’ samples (p=0.280).   
 
There was no statistical difference between the number of bacteria cultured per sample 
based on the Bartlett score (p=0.620) or between the type of bacteria cultured based on the 
Bartlett score of the sample (p=0.812).  
 
All analyses were done with all the samples included, irrespective of the Bartlett score. All 
analyses were also repeated dividing the samples into their different Bartlett score groups 
(-1 and -2 vs. 0 vs. +1 and +2). There was no difference between the results obtained when 
comparing the different groups amongst themselves or against the group with all the 
samples included.  
 
3.4.4 Number of Bacteria Cultured per Sample  
Forty-five (25.7%) samples did not culture any bacteria. Sixty-two (35.4%) cultured 1 
bacteria, 47 (26.9%) 2 bacteria, 18 (10.3%) 3 bacteria and 3 (1.7%) samples cultured 4 
bacteria (Table 3.2). There was no statistical difference between HIV positive and HIV 
negative patients when comparing positive and negative cultures (p=0.417), and comparing 
the number of bacteria cultured per sample. (p=0.488).  
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3.4.5 Density of Individual Bacterial Colonies 
The density of the individual bacterial colonies was as follows: no colonies were described 
as scanty, 5 (2.3%) had 1+ growth, 46 (20.7%) had 2+ growth and 169 (76.1%) had 3+ 
growth. Data was missing on 2 samples (Table 3.2). There was no statistical significance 
between the density of the colonies in HIV + and HIV – patients’ samples (p=0.387).  
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Table 3.2 Characteristics of all Samples Collected  
Specimens Number (%) P - value 
 Total  
 
HIV +ve HIV -ve HIV +ve vs. 
HIV –ve 
Number of samples per patient 
 
- 1 
- 2  
- 3 
- >3 
 
  n = 78 
 
34 (43.6) 
22 (28.2) 
  8 (10.3) 
14 (17.9) 
n = 62 
 
29 (46.8) 
17 (27.4) 
  6 (9.7)  
10 (16.1) 
n = 16 
 
5 (31.3) 
5 (31.3) 
2 (12.5) 
4 (25.0) 
p = 0.701 
Types of samples  
 
- Expectorated and induced sputum 
- Broncho-alveolar lavage           
                              
n = 175 
 
150 (85.7) 
  25 (14.3) 
     
n = 133 
 
123 (92.5) 
  10 (7.5) 
n = 42 
 
27 (64.3) 
15 (35.7) 
p = <0.05 
 
 
 
Quality of expectorated and induced 
sputum     
 
- Sample representative of upper 
airways 
- Unsure regarding upper or lower  
airway representation 
- Sample representative of lower 
airways 
- Missing data 
 
n = 150* 
   
 
  11 (7.3) 
 
  29 (19.3) 
 
109 (72.7) 
 
    1 (0.7) 
 
 n = 122 
 
 
  10 (8.2) 
 
  21 (17.2) 
 
  91 (74.6) 
 
 
n = 27 
 
   
  1 (4.2) 
 
  8 (29.6)  
 
18 (66.7) 
 
 
p = 0.291 
Number of bacteria cultured per 
sample  
 
- 0 
- 1 
- 2 
- 3 
- 4 
                  
n = 175** 
 
 
45 (25.7) 
62 (35.4) 
47 (26.9) 
18 (10.3) 
  3 (  1.7) 
n = 133 
 
 
36 (27.1) 
48 (36.1) 
32 (24.1) 
14 (10.5)  
  3 (2.3) 
n = 42 
 
 
  9 (21.4) 
14 (33.3) 
15 (35.7)  
  4 (9.5)  
  0 (0.0) 
p = 0.488 
 
 
 
 
 
 
 
 
Density of all individual bacterial 
colonies 
 
- Scanty 
- <10 CFUs*** on initial inoculum 
- 10-99 CFUs on initial inoculum 
- ≥100 CFUs on initial inoculum 
- Missing data 
 
n = 220 
 
    
    0 
    5 (2.3) 
  46 (20.7) 
169 (76.1) 
    2 (0.9) 
 
n = 164         
 
 
    0  
    5 (3.1) 
  33 (20.1) 
126 (76.8) 
    0 
n = 56 
   
 
  0  
  0 
13 (23.2) 
43 (76.8) 
  0 
p = 0.387 
* Excludes BAL samples ** Includes BAL samples ***Colony-forming units 
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3.5 Names and Types of Bacteria Cultured 
The total number of bacterial colonies grown from the 175 samples of the 78 patients was 
222.  The bacteria cultured were H. Influenza (n= 80, 36%), S. pneumonia (n=28, 13.1%), 
S. aureus (n=25, 11.3%), M. catarrhalis (n=25, n=10.8%), H. parainfluenzae (n=15, 
6.8%), Pseudomonas species (n=14, 6.3%), Klebsiella species (all producing extended 
spectrum beta-lactamase) (n=11, 5.0%), E. coli (n=6, 2.7%), Enterobacter species (n=4, 
1.8%), and others (n=17, 6.4%) (Figure 3.1).  The majority of bacteria (n=159, 71.6%) 
cultured were gram negative bacteria and the rest were gram positive bacteria (n=63, 
28.4%) (Table 3.3).  
 
The common gram positive bacteria cultured were Streptococci, 58.7% and Staphylococci, 
41.3%. The common Streptococci grown were S. pneumoniae (78.4%). Other streptococci 
grown were S. viridans (n = 1), S. pyogenes (n = 5) and others (n = 2). The common 
Staphylococci were Methicillin sensitive S. aureus, 69.2%. Other Staphylococci were 
Methicillin resistant S. aureus and only 1 (3.8%) was a coagulase-negative staphylococcus.  
 
The common gram negative bacteria were H. influenzae (n=80, 50.3%), M. catarrhalis (n 
= 24, 15.1%), H. parainfluenzae (n=15, 9.4%), Pseudomonas species (n=14, 8.8%) and 
Klebsiella species (all extended spectrum beta-lactamase producing organisms) (n=11, 
6.9%). The other gram-negative bacteria were E. coli (all extended spectrum beta-
lactamase producing organisms) (n=6, 3.8%), Enterobacter species (n = 4, 2.5%) and a 
few of M. morgagni, Proteus mirabilis, Pantoea species and Neisseria species (n=5, all 
combined). 
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Figure 3.1: Type, Number and Percentage of Bacteria Cultured in all Airway Samples 
 
*Ps. aeruginosa and Ps. flourescens, ** Coagulase negative staphylococcus, S. viridans, S. pyogenes and 
Group C + G Streptococcus, ** M. morgagni, P. mirabilis, Pantoea species and Neisseria spp. 
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Table 3.3 Characteristics and Number of Bacteria Cultured in all Samples (n=222)  
Bacteria Numbers (%) P - value 
 
 
 
All 
 
 
HIV +ve HIV -ve 
 
 
HIV +ve 
 vs.       
HIV –ve 
 
Gram positive bacteria: 
 
Streptococci (n=37) 
 
- S.pneumoniae 
- Other streptococci
1
  
 
Staphylococci (n=26) 
 
- Methicillin sensitive S.aureus 
- Methicillin resistant S.aureus 
- CNS
2
 
 
 
  63/222 (28.4) 
 
    37/63 (58.7) 
   
    29/37 (78.4) 
      8/37 (21.6) 
 
    26/63 (41.3) 
 
    18/26 (69.2) 
      7/26 (26.9) 
     1/26 (3.8) 
 
46/63 (73.0) 
 
26/37 (70.3) 
 
22/29 (75.9) 
    4/8 (50.0) 
 
20/26 (76.9) 
 
15/18 (83.3) 
    5/7 (71.4) 
    0/1 (0.0) 
 
17/63 (27.0) 
 
11/37 (29.7) 
 
  7/29 (24.1) 
    4/8 (50.0) 
 
  6/26 (23.1) 
 
  3/18 (16.7) 
    2/7 (28.6) 
    1/1 (100) 
 
 
p = 0.413 
 
p = 0.308 
 
p = 0.545 
p = 0.113 
 
p = 0.501 
 
p = 0.288 
p = 0.564 
 
Gram negative bacteria: 
 
H.influenzae 
M.catarrhalis 
H.parainfluenzae 
Pseudomonas
3
             
 
Klebsiella species (All ESBL) 
E.coli (All ESBL) 
Enterobacter species 
Other Gram negative bacteria
4 
 
 
All ESBL organisms 
 
159/222 (71.6) 
 
  80/159 (50.3) 
  24/159 (15.1) 
   15/159 (9.4) 
   14/159 (8.8) 
    
   11/159 (6.9) 
     6/159 (3.8) 
     4/159 (2.5) 
     5/159 (3.1) 
 
   
17/159 (10.7) 
 
120/159 (75.5) 
 
   61/80 (76.3) 
   20/24 (83.3) 
   13/15 (86.7) 
     5/14 (35.7) 
      
      9/11 (81.8) 
        6/6 (100) 
 
 
 
     
15/17 (88.2) 
 
 
39/159 (24.5) 
 
19/80 (23.8) 
  4/24 (16.7) 
  2/15 (13.3) 
  9/14 (64.3) 
   
  2/11 (18.2) 
     0/6 (0.0) 
 
 
 
   
   2/17 (11.8) 
 
p = 0.413 
 
p = 0.405 
p = 0.224 
p = 0.221 
p = 0.002 
 
p = 0.445 
p = 0.171 
 
 
 
 
p = 0.148 
 
1
S. viridans, S. pyogenes and Group C + G streptococci, 
2
Coagulase negative staphylococcus, 
3
Ps. aeruginosa 
+ Ps. flourescens,  
4
M. morgagni, P. mirabilis, Pantoea and Neisseria species 
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3.6 Comparisons of the Types of Bacteria Cultured in HIV Positive and Negative 
Patients  
When comparing HIV positive and negative patients with regards to bacteria cultured in 
individual samples there was no statistical difference with regards to the presence of gram 
positive and gram negative bacteria (p = 0.844)  (Figure 3.2).  
 
Figure 3.2: Comparison of Bacteria Cultured in Individual Samples between HIV Positive 
and Negative Patients 
 
* P=0.002 for Pseudomonas **  
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There was also no statistical difference for streptococci (p=0.308), S. pneumoniae 
(p=0.545) and other streptococci (p=0.113), staphylococci (p=0.501), MSSA (p=0.288) 
and MRSA (p=0.564).   
 
There was no statistical difference with most gram negative bacteria including H. 
influenzae (p=0.416), M. catarrhalis (p=0.224), H. parainfluenzae (p=0.221), ESBL 
Klebsiella (p=0.445) and ESBL E. coli (p=0.171).  
 
Similarly there was no statistical difference between groups when the ten most common 
bacteria were combined for analysis (p=0.357), when all gram positive bacteria were 
combined for analysis (p=0.413), when all gram negative bacteria were combined for 
analysis (p=0.413) and when all ESBL organisms were combined for analysis (p=0.148). 
 
When comparing the presence of Pseudomonas in the individual samples of HIV positive 
and HIV negative patients statistical significance was reached (p=0.002) with HIV 
negative patient samples more likely to culture Pseudomonas. Similarly when the presence 
of the five most common bacteria per individual sample was compared in HIV positive and 
HIV negative patients statistical significance was reached (p=0.024) with HIV positive 
patients more likely to have one of the five most common bacteria in an individual sample. 
 
When looking at the number of patients who ever cultured a specific bacteria and then 
comparing HIV positive and HIV negative patients no statistical difference was found for 
H. influenzae (p=0.450), S. pneumoniae (p=0.337), S. aureus (p=0.612), M. catarrhalis 
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(p=0.481), H. parainfluenzae (p=0.194), ESBL Klebsiella species (p=0.666) or  
Pseudomonas species (p=0.148) (Figure 3.3). 
 
Figure 3.3: Comparison of Bacteria Cultured in Individual HIV Positive and HIV 
Negative Individuals 
 
 
3.7 Density of Individual Bacterial Colonies 
The colony densities of the individual bacteria are shown in Figure 3.4. S. aureus was 
statistically more likely to be present with 10 – 99 colony-forming units per inoculum 
when compared to all the other bacteria cultured who were more likely to be present with 
>100 colony-forming units per inoculum. 
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When looking at the densities of the individual bacterial colonies and comparing these 
between HIV + and HIV – patients there was no statistical significance for H. influenzae 
(p=0.296), S. pneumoniae (p=0.155), S. aureus (p=0.443), M. catarrhalis (p=0.710), H. 
parainfluenzae (p=0.921), Klebsiella species (p=0.118) and Pseudomonas species 
(p=0.346).  
 
Figure 3.4: Density of Colony Forming Units on Bacterial Culture.  
 
* P<0.05 for S.aureus 
 
When grouping the density categories into the following two groups: scanty to 99 CFUs 
and >100 CFUs on initial inoculum, there was no statistical difference between the HIV + 
and HIV – groups when looking at individual bacterial densities. 
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There was no statistical difference between HIV + and HIV – patients when comparing the 
types and percentage of bacteria with more than 100 CFUs.  
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CHAPTER 4  
4.0 DISCUSSION AND CONCLUSION 
4.1 Discussion 
A number of studies have reported on bacteria colonizing the airways of children with 
bronchiectasis, with most of them reporting from countries with a low incidence of HIV 
infection in children.
6, 8, 14, 16, 19, 22, 26, 29, 40, 42
 Very few of these studies have reported on 
colonization of children who are HIV positive.
39, 44
 It is not known whether there is a 
difference between the number, type and density of bacteria cultured in the airways of HIV 
positive and HIV negative children with bronchiectasis. The aim of this study was to 
determine which bacteria are isolated from the airways of children with bronchiectasis and 
whether there are differences in the type of bacteria cultured in the airways between HIV 
positive and HIV negative children.  
 
The main findings in this study were that majority of patients with bronchiectasis were 
HIV positive with active disease as shown by low CD4 count and high viral loads. The 
bronchiectasis was most likely secondary to previous severe and recurrent lung infections. 
Most of the HIV positive patients also had a previous history of being treated for TB.  
 
The most common bacteria cultured from the airways of children with bronchiectasis were 
H. influenzae, S. pneumoniae, S. aureus, M. catarrhalis and H. parainfluenzae. When 
comparing the bacteria cultured from the airways of HIV positive and HIV negative 
children with bronchiectasis there was no difference between the numbers of bacteria 
cultured per airway sample, the type of bacteria cultured per sample or per individual 
patient and the density of the bacterial colonies cultured in the children. The number, type 
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and density of bacteria cultured in children with bronchiectasis were not associated with 
their HIV status.  
 
In this study about three quarters (74.3%) of specimens had at least one bacteria cultured,   
with 38.9% of them culturing two or more types of bacteria. This is a high rate of positive 
cultures compared to that reported in other studies.
8, 39
 Karadag et al, isolated bacteria in 
only 46.9% of patients with bronchiectasis, and cultured one bacteria in 66.1% of patients. 
The reason for this difference is not clear, but it could be related to the age at presentation 
of the patients and that the majority of our patients were HIV positive, though we did not 
find differences in bacteria density between HIV negative and positive patients.  The mean 
age of the patients in the Turkish cohort was 7.4 ± 3.7 years at presentation while the mean 
age of our patients was 9.7 ± 3.3 years. This would allow more time for the untreated 
patients to acquire more acute infective exacerbations and possibly to be colonised by a 
larger number of organisms.  Ferrand reported on a cohort of adolescents with HIV 
associated lung disease and reported positive bacterial cultures on only 33% of their 
patients.
39
 This low rate of positive cultures in this cohort is most likely due to the fact that 
this study looked at children with all HIV associated chronic lung disease where only 43% 
patient of the patients had bronchiectasis, compared to this study where all patients had 
bronchiectasis.   
 
The high rate of positive samples is similar to some studies reporting from countries with 
low HIV incidence in children.
6, 7, 14, 16, 19
 In a study by Twiss et al they cultured bacteria in 
75% of samples
19
, while Kapur cultured bacteria in 62% and 68% of their samples 
respectively in two different studies
14, 16
 and Edward cultured bacteria in 66.7% of their 
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samples.
6
 Even though all these studies were performed in settings with a very low HIV 
prevalence these studies’ results compare favourably with this study’s results.  Masekela, 
in a study from South Africa had reported a positive culture rate of 65% when cumulative 
samples over a one year period were included.
44
 
 
Gram negative bacteria were cultured more commonly than gram positive bacteria in this 
cohort (71.6% vs. 28.4%). This is in keeping with all the paediatric studies looking at 
bacteria in the airway of children with bronchiectasis.
6, 8, 14, 16, 19, 22, 26, 29, 39, 42, 44
 The 
bacteria most commonly cultured in our study were: H. influenzae (36%), S. pneumoniae 
(13.1%), S. aureus (11.3%), M. catarrhalis (10.8%) and H. parainfluenzae (6.8%). These 
results are very similar to the results reported from different countries where similar 
studies have been done.
6, 8, 14, 19, 22, 26, 29, 42
  
 
H. influenzae is the most common bacteria reported in most studies with a frequency 
ranging between 31% and 68%, and the frequency in this study was 36%. The majority of 
studies have reported similar results in terms of the top 5 bacteria cultured namely H. 
influenzae followed by S. pneumoniae, M. catarrhalis, H. parainfluenzae and S. aureus.
14, 
19, 22, 26
 Other studies have reported common bacteria that vary slightly from this study, 
with Dagli, Karadag and Li all reporting, in order of declining frequency, H. influenzae, 
Ps. aeruginosa, S. aureus, and S. pneumoniae.
8, 29, 42
 The bacteria from these studies are 
similar to this study except for a higher frequency of Ps. aeruginosa found in their cohorts. 
The reason for this finding is not clear but it was reported by Kapur in one of their studies 
that the presence of Ps. aeruginosa colonisation of the airways of the non-CF child with 
bronchiectasis could signal the presence of a serious underlying co-morbidity.
16
 Indeed in 
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the only case of Ps. aeruginosa in the airways of children without CF found by Edwards 
was in a patient with a tracheostomy.
7
 
 
Masekela found that in samples from children who are HIV infected and have 
bronchiectasis  the most commonly cultured bacteria were H. influenzae (30%) and H. 
parainfleunzae (21%) with M. catarrhalis following at 4% and none of S. pneumoniae, S. 
aureus or Ps. aeruginosa reaching a frequency of more than 2%.
44
 These findings are very 
different to the ones in this study with a much higher frequency of H. parainfluenzae and 
much lower frequency of all the other bacteria. The reason for this difference is unclear. In 
the study by Ferrand the findings were similar to this study, but with a lower frequency of 
S. pneumonia and a higher frequency of S. aureus.
39
 The numbers in the study were very 
small and therefore difficult to interpret.  
 
There was no difference in this study between the HIV positive and HIV negative patients 
with regards to the presence of gram positive or gram negative bacteria and there was no 
difference between HIV positive and HIV negative patients with regards to the presence of 
H. influenzae, S. pneumoniae, S. aureus, M. catarrhalis or H. parainfluenzae in individual 
airway samples or in all samples collected per patient.  
 
There was a higher frequency of Ps. aeruginosa in samples of HIV negative children than 
in those who were HIV positive (P < 0.05). When reanalysing the data on an individual 
patient basis, and not on a total airway sample basis, it was found that one patient had 
multiple samples positive for Ps. aeruginosa and there was no statistical difference 
between HIV positive and HIV negative patients in relation to the frequency of Ps. 
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aeruginosa in their airway samples (P = 0.148). There was also no difference in the 
densities of the individual bacterial colonies between HIV positive and HIV negative 
patients.  
 
There are a number of limitations to this study. Firstly, it was a retrospective observational 
study and therefore it is possible that some of the information reviewed was not complete 
for some patients. Secondly, CT scans of the chest were not obtained on all patients to 
confirm the presence of bronchiectasis. Lastly, the number of HIV negative patients in this 
study was quite small. Though the number of HIV negative patients was much smaller than 
the HIV positive patients the strengths of this study is that a direct comparison in number, 
types of bacteria grown in the samples from airways of HIV positive and HIV negative 
patients was made, which has not been reported in previous studies.  
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4.2 Conclusion and Recommendations 
The most common bacteria cultured in the airway samples of paediatric patients with 
bronchiectasis were: H. influenzae (36%), S. pneumoniae (13%), S. aureus (11%), M. 
catarrhalis (11%) and H. parainfluenzae (7%). 
 
There is no difference in the type of bacteria nor the density of the bacterial colonies 
cultured in the airways of children with bronchiectasis with regards to their HIV status. 
  
Antibiotics used during an acute exacerbation in patients with bronchiectasis should be 
based on the results of an individual’s own sputum culture if available or else an antibiotic 
with both gram positive and gram negative cover, including cover for both S. pneumoniae 
and H. influenzae should be used. 
 
Antibiotics used in the treatment of an acute exacerbation in patients with bronchiectasis 
should not differ depending on the HIV status of the patient.  
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APPENDIX 1: DATA CAPTURE SHEET 
 
Bacteria found in the airway samples of a cohort of paediatric 
patients with bronchiectasis: Data Capture sheet 
 
Dr Charl Verwey 082 411 8656 
 
 
Patient Study Nr:                 □□1 
 
 
Date enrolled: (dd/mm/ccyy): ___/___/______        □□□□□□□□2   
 
 
Patient age (months): ___________________           □□□3 
 
            
 
Inclusion / exclusion criteria 
 
Age < 16 years:         Y / N  
Bronchiectasis confirmed:       Y / N  
≥ 1 airway sample collected (CHBAH):     Y / N  
Known diagnosis of cystic fibrosis      Y / N  
 
 
Basics 
 
Date of presentation to Resp. team: ___/___/______    □□□□□□□□4 
First presentation:      Ward
1
 / Clinic
2
      □5 
 
Bronchiectasis diagnosis: 
 Clinical dx:       Y1 / N2    □6 
 Radiological dx:      Y1 / N2     □7 
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History         Study Nr: 
Aetiology of bronchiectasis:         □□8
  
1. Post-infectious (excl. TB):       
2. Post-Tuberculosis:         
3. Post-Foreign body (intraluminal obstruction)   
4. Primary immunodeficiency      
5. HIV acquired immunodeficiency     
6. Acquired immunodeficiency (excl. HIV)    
7. Mucociliary abnormalities (CF / PCD)    
8. Congenital airway abnormalities   
9. Cough abnormalities       
10. Aspiration syndromes       
11. Unknown  
12. Other        
 
Duration of symptoms (months): _________           □□□9 
 
 
 
Radiology 
Chest X-ray available:     Y
1
 / N
2
       □10 
 If yes:  Bronchiectasis confirmed: Y1 / N2        □11 
 If yes:    Unilateral1 / Bilateral2       □12 
Number of lobes involved: _______       □13  
Chest CT done:      Y
1
 / N
2
        □14 
 If yes: Bronchiectasis confirmed: Y1 / N2        □15 
 If yes:     Unilateral1 / Bilateral2       □16 
Number of lobes involved_______               □17 
Type of bronchiectasis:Tub
1
/Vari
2
/Cys
3
/Combo
4         □18 
 
Other findings: ______________________________ 
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Laboratory         Study Nr: 
HIV test done:     Y
1
 / N
2
          □19  
 If yes:    PCR1 / Elisa2        □20 
 Result conclusion: HIV positive1 / HIV negative2       □21 
 
 
HIV positive:CD4 count(x10
6
/l/%):______/_____    □□□□/□□,□22 
  Viral load(cps/ml):____________       □□□□□□□23 
  ARVs:     Y
1
 / N
2
        □24 
- If yes:  Duration (months) _______     □□□25 
 
Previous TB treatment:     Y
1
 / N
2
        □26 
If yes: Number of treatments:   ________       □27 
 
Currently on TB treatment:    Y
1
 / N
2
       □28
 If yes: duration of treatment (months)  ________        □29 
 
Currently on Bactrim prophylaxis:   Y
1
 / N
2
       □30 
If yes: duration of treatment (months)  _________     □□□31 
 
Nr of airway samples collected:    __________        □□32 
 
Type of samples collected:            □33 
1. Spontaneous expectoration:   Nr:        □34 
2. Induced expectoration:   Nr:        □35 
3. Tracheal aspirates:    Nr:      □36 
4. Broncho-alveolar lavage:   Nr:        □37 
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Sample Nr:  Date:      Study Nr:  
 
Type of sample:    ES
1
 / IS
2
 / TA
3
 / BAL
4
        □38 
Adequacy of sample: Bartlett score   -2
1
 / -1
2
 / 0
3
 / 1
4
 / 2
5
        □39 
Gram stain:      Positive
1
 / Negative
2
        □40 
If positive:  Neutrophils:  1+
1
 / 2+
2
 / 3+
3
        □41 
Epithelial cell:  1+
1
 / 2+
2
 / 3+
3
         □42 
   Bacteria:  +
1
 / ++
2
 / +++
3
        □43 
  Organism: Gram +
1
 / Gram –2 / Combo3: _____          □44 
Culture:      Positive
1
 / Negative
2
        □45 
 
 If positive:    Normal flora1 / Pathological2        □46 
 If pathological: No of Organisms:  11 / 22 / 33        □47 
- Organism 1:   ____________________   □4 
- No of colonies:  scanty1 / 1+2 / 2+3 / 3+       □49 
 
- Organism 2:  ____________________       □50 
- No of colonies:  scanty1 / 1+2 / 2+3 /   □51 
 
- Organism 3:  ____________________        □52 
- No of colonies:  scanty1 / 1+2 / 2+3 / 3+4 □53 
 
 Fungal culture:    positive1 / negative2        □54 
- If positive: organism:  ____________________       □55 
 TB identified (smear or TBC)  Y1 / N 2         □56 
 
Notes: 
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APPENDIX 2: GOOD CLINICAL PRACTICE CERTIFICATE 
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APPENDIX 3: HOSPITAL PROTOCOL REVIEW COMMITTEE 
CERTIFICATE 
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APPENDIX 4: HUMAN RESEARCH ETHICS COMMITTEE  
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APPENDIX 5: PLAGIARISM REPORT 
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